Tim Barberich is a founder of Sepracor, Inc., a publicly-traded and fully integrated research pharmaceutical company. He served as Sepracor’s Chief Executive Officer and Chairman for more than 20 years, where he grew revenues to more than a billion dollars through the successful partnering and commercialization of several products, including Allegra®, Clarinex®, Lunesta® and Xopenex®. In 2009, Sepracor, now known as Sunovion, was acquired by Dainippon Sumitomo to form one of the largest Japanese-based global pharmaceutical companies. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation, a major supplier of research tools to the life sciences industry. He also served on the Board of Trustees of Boston Medical Center and the Pharmaceutical Research and Manufacturers’ Association. Mr. Barberich is a graduate of Kings College and holds a B.S. degree in Chemistry.